13F Pro

SEC Form 4 reporting owner

Panacea Innovation Ltd

Panacea Innovation Ltd has filed 4 Form 4 transactions reported between January 12, 2026 and May 7, 2026, as a reporting owner of Atara Biotherapeutics, Inc..

Name as filed: Panacea Innovation Ltd

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$3.7M
2 lines
Companies
1
with Form 4 filings
Latest transaction
May 7, 2026
transaction date

Roles and reported holdings

  • ATRAAtara Biotherapeutics, Inc.
    Jan 12, 2026 – May 7, 2026

    Reporting owner

    Held indirectly (latest line)1,011,000 sh as of May 7, 2026 · Form 4

    24 months: $3.7M sold

Transaction history

All 4 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
May 7, 2026ATRAOpen-market saleCode S · indirect313,446$3.2M@ $10.10Form 4
Mar 17, 2026ATRAShares withheld for tax or exercise priceCode F · indirect5$26@ $5.23Form 4
Mar 17, 2026ATRAOption exerciseCode M · indirect259,163$26@ $0.0001Form 4
Jan 12, 2026ATRAOpen-market saleCode S · indirect80,554$489K@ $6.07Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.